Intelligence Feed event · Equity · 2026-10-04

    DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth

    Question

    DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth

    Direct answer

    DaVita HealthCare closed at $178.69, outperforming the S&P 500 during the session as investors evaluated upcoming quarterly earnings. The dialysis provider is projected to deliver earnings of $3.78 per share, a 50.6% increase over the prior-year quarter, while maintaining a valuation discount at 12.1x forward earnings versus the industry benchmark of 19.68x.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/davita-trades-at-12-1x-forward-p-e-ahead-of-projected-50-6-q3-earnings-growth-4602b3

    EQUITY
    DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth
    DaVita HealthCare closed at $178.69, outperforming the S&P 500 during the session as investors evaluated upcoming quarterly earnings. The dialysis provider is projected to deliver earnings of $3.78 per share, a 50.6% increase over the prior-year quarter, while maintaining a valuation discount at 12.1x forward earnings versus the industry benchmark of 19.68x.
    DVA
    Impact
    59
    OCT 4
    SIG
    80%
    DVA
    DaVita Trades at 12.1x Forward P/E Ahead of Projected 50.6% Q3 Earnings Growth
    DaVita HealthCare closed at $178.69, outperforming the S&P 500 during the session as investors evaluated upcoming quarterly earnings. The dialysis provider is projected to deliver earnings of $3.78 per share, a 50.6% increase over the prior-year quarter, while maintaining a valuation discount at 12.1x forward earnings versus the industry benchmark of 19.68x.
    → A 50.6% EPS expansion against a 12.1x forward P/E multiple creates valuation rerating potential relative to the 19.68x industry average.
    Impact
    DaVita HealthCare closed at $178.69, outperforming the S&P 500 during the session as investors evaluated upcoming quarterly earnings. The dialysis provider is projected to deliver earnings of $3.78 per share, a 50.6% increase over the prior-year quarter, while maintaining a valuation discount at 12.1x forward earnings versus the industry benchmark of 19.68x.
    Affected
    DVA
    Transmission
    A 50.6% EPS expansion against a 12.1x forward P/E multiple creates valuation rerating potential relative to the 19.68x industry average.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    DVAearnings expansion against discounted forward multipleUp1-4wDVA trades at 12.1x forward P/E versus 19.68x industry average with 50.6% EPS growth

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month